Supplementary figure 4 from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative
| Autor: | Frédéric Amant, Tjalling Bosse, Philippe Moerman, Els Hermans, Ellen Gommé, Debby Thomas, Godelieve Verbist, Miriam Mints, Eva Wardelmann, Michael R. Mallmann, Leonardus F. Massuger, Ronald P. Zweemer, Carole Mestdagh, Maciej Stukan, Helga B. Salvesen, Farid Moinfar, Johannes Haybaeck, Olli Carpén, Jutta Huvila, Pavel Dundr, Michal Zikan, Mariël Brinkhuis, Roy P.M. Kruitwagen, Koen Van de Vijver, Angel Garcia-Jimenez, Eva Colas, Natalja ter Haar, Jone Trovik, An Coosemans, Daniela Annibali, Tine Cuppens |
|---|---|
| Rok vydání: | 2023 |
| DOI: | 10.1158/1078-0432.22466289 |
| Popis: | Combination of the mTORC1/2 inhibitor TAK-228 and the PI3K-α inhibitor alpelisib inhibits EMC041 tumor growth to the same extent as BEZ235 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|